Current filters:


Popular Filters

1950 to 1974 of 2255 results

Future for biosimilars hugely promising, Momenta CEO tells GPhA meeting


Craig Wheeler, chief executive of Momenta Pharmaceuticals (Nasdaq: MNTA) discussed the promise and prospects…

BiotechnologyGenericsMarkets & MarketingMomenta PharmaceuticalsResearch

Auxilium and Actelion partner on Xiaflex


biotech firm, have entered into a long-term partnership for the development, supply and commercialization…

ActelionAuxilium PharmaceuticalsBiotechnologyLicensingPharmaceuticalRare diseasesXiaflex

EMA approves Shire Vpriv plant in USA


Ireland-headquartered biopharma firm Shire (LSE: SHP) says that the European Medicines Agency's Committee…

BiotechnologyFinancialNorth AmericaPharmaceuticalRare diseasesRegulationReplagalShireVpriv

Boehringer Ingelheim links with Xencor on MAb supply


Independent German drug major Boehringer Ingelheim has entered into a collaboration agreement with USA-based,…

BiotechnologyBoehringer IngelheimLicensingPharmaceuticalXencor

BASF debuts white biotech research lab in USA


Germany-headquartered BASF (BAS: DE), the world’s biggest chemical company, has opened a new white…

BASFBiotechnologyNorth AmericaResearch

Ligand licenses DARA Program to Retrophin


USA-based Ligand Pharmaceuticals (Nasdaq: LGND) has entered into an agreement in which it has licensed…

BiotechnologyDARALicensingLigand PharmaceuticalsNephrology and HepatologyPharmaceuticalRare diseasesResearchRetrophin

GSK exercises option for Galapagos drug candidates


Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Clazosentan for traumatic brain injury shows promise in animals


A new drug is showing promise in shielding against the harmful effects of traumatic brain injury (TBI)…


Setback for Gilead’s oral hep C drug candidate


There was disappointment for US biotech firm Gilead Sciences (Nasdaq: GILD) last Friday, when the company…

Anti-viralsBiotechnologyGilead SciencesResearch

uniQure to acquire Amsterdam Molecular Therapeutics business


Netherlands-based human gene based therapies developer Amsterdam Molecular Therapeutics (Euronext: AMT)…

Amsterdam MolecularBiotechnologyMergers & AcquisitionsuniQure

Critical Pharma links with academia on osteoporosis nasal spray


Critical Pharmaceuticals, an emerging UK biotechnology company, and The University of Nottingham, UK,…

Anti-Arthritics/RheumaticsBiotechnologyCritical PharmaceuticalsForteoResearchteriparatide

Karo Bio drops eprotirome and split up plans


There was a double-dose of bad news for Sweden’s Karo Bio (STO: KARO), which this week said it would…

BiotechnologyCardio-vasculareprotiromeKaro BioMergers & AcquisitionsPharmaceuticalRegulation

Impending biologics patent expiries creates huge opportunity for European biosimilars makers


The biosimilars manufacturing industry is at a nascent stage. However, the impending patent expiries…

BiotechnologyEuropeGenericsMarkets & MarketingPatents

Biogen Idec in deal to buy Stromedix


S biotech firm Biogen Idec (Nasdaq: BIIB) has entered into a definitive agreement to acquire Stromedix,…

Biogen IdecBiotechnologyMergers & AcquisitionsStromedix

US FDA priority review for Truvada for reducing HIV risk


The US Food and Drug Administration has accepted the supplemental New Drug Application and granted a…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

Valeant bags another company, Eyetech


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says that it has agreed…

BiotechnologyEyetechMacugenMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Regeneron ups Eylea forecast, posts 2011 results


USA-based biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares leap 12% to $114.10 in…


Legal provisions take toll on Actelion


Switzerland-based Actelion (ATLN: VX), Europe’s largest biotech company, this morning posted full-year…


US Rx cough/cold deal boosts Vernalis


UK biotech firm Vernalis (LSE: VER) saw its share price rocket 28% to 25.2 pence last Friday, when the…

BiotechnologyLicensingNorth AmericaResearchRespiratory and PulmonaryTris PharmaVernalis

Kineret halts organ damage in inflammatory genetic disorder


A new study shows that Kineret (anakinra), a drug developed by US biotech giant Amgen (Nasdaq: AMGN)…

AmgenBiotechnologyKineretPharmaceuticalRare diseasesResearch

1950 to 1974 of 2255 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top